WaPo on gold advertising and right-wing media

 I’m quoted in the story.

from Blogger http://tushnet.blogspot.com/2023/07/wapo-on-gold-advertising-and-right-wing.html

Posted in Uncategorized | Tagged , | Leave a comment

Defendant’s belief its ads were effective is evidence of injury

Sandoz Inc. v. Amgen Inc., 2023
WL 4681569
,
No. 2:22-cv-05326-RGK-MARx
(C.D. Cal. Jun. 29, 2023)

Sandoz brought state and federal
false advertising claims against Amgen for its advertising of
Neulasta, a pegfilgrastim injection used to treat the
immunity-reducing side effects of chemotherapy, in particular the risk of the
life-threatening infection febrile neutropenia (FN), by stimulating the
production of neutrophils, a
type of
white blood cell that helps the body fight infections.

Thanks to its patents, Amgen enjoyed a temporary exclusivity period for pegfilgrastim injections until 2015. In 2014, Amgen introduced
Onpro, a new method for delivering Neulasta through an “on-body injector.” With
Onpro, patients could receive timed pesfilgrastim injections the day after
chemotherapy without returning to the healthcare facility. The first
pegfilgrastim biosimilar hit the market in November 2018, and would ultimately
be followed by five others, including
Sandoz’s
Ziextenzo in November 2019.

A few months after Ziextenzo
launched, Amgen
launched a multi-million-dollar ad
campaign to promote Onpro. These ads claimed that “Pegfilgrastim PFS resulted
in a significantly higher risk of FN vs. Onpro” and “[w]ith PFS, FN incidence
increased by 31% vs Onpro.” These ads were based on an obseivational study
Amgen
conducted itself, in an effort to remain competitive with
the emerging biosimilar market.
But the
FDA,
independent reviews at scientific journals, and even some of
Amgen’s
own employees criticized the advertising claims as
unsupported and misleading.
A second Amgen
study received similar criticism. But Amgen continues to run its ads, now with updated claims that
Onpro lowered the incidence of FN by 36% as compared to pegfilgrastim PFS based
on its new study.
Amgen saw the ads as successful, believing that they
increased sales and convinced customers not to switch to biosimilars.

Ziextenzo did not perform well at
launch
, but the true cause was disputed
.
Amgen argued that there was no impact because the ads didn’t refer to Sandoz or
Ziextenzo, and Sandoz couldn’t identify a single patient, prescriber, or
insurer
that would have used Ziextenzo but
chose Onpro because of
the
advertising
claims.
After all
: (1) Ziextenzo was not
the first biosimilar on the market; (2) Ziextenzo was not reimbursable by
Medicare; (3) Ziextenzo was more expensive than both Onpro and its biosimilar
competitors; and (4) the COVID-19 pandemic drove a higher demand for on-body
injectors like Onpro because on-body injectors minimized patients’ need to
travel to healthcare facilities.
But Sandoz’s experts claimed over $32
million in lost net profits even after accounting for these.

Injury: Damages and disgorgement under
the Lanham Act require injury (for false advertising, not trademark
infringement, despite the same statutory language covering both; no, I am not
going to stop pointing this out any time soon).
Proving an injury through lost sales data can be
challenging because lost sales are often “predicated on the independent decisions
of third parties; i.e., customers.” Thus, “[a] plaintiff who can’t produce lost
sales data may therefore establish an injury by creating a chain of inferences
showing how defendant’s false advertising could harm plaintiff’s business.” Such
an inference may be established through economic models using “actual market
experience and probable market behavior.”

The evidence here, including direct
competition between the parties, would allow a jury to reasonably infer injury:

Ziextenzo was
among the handful of pegfilgrastim biosimilar PFS products on the market in
late 2019.
According to Defendant’s internal
memoranda, the advertising campaign was designed to “optimally position Onpro in
[the] face of biosimilar competition.” These ads ultimately succeeded, driving
89,000 additional units by Defendant’s own estimates. From these facts, a
jury
could reasonably infer that the entire pegfilgrastim
biosimilar market lost sales as a direct result of Defendant’s advertising. And,
because Ziextenzo was one of those biosimilars, a jury could further infer that
Ziextenzo lost sales, thereby causing Plaintiff an injury.

Although some cases disparage
defendants’ own expectations and beliefs about causation as evidence of injury (in
false advertising cases; never in TM cases), I believe this is both the
majority and the correct rule. The court found Amgen’s evidence corroborated by
Sandoz’s experts,
who opined that the entire biosimilar
market suffered as a result of Defendant’s advertising.
Courts routinely find expert testimony sufficient evidence
of an injury to survive summary judgment. And economic analysis is a valid
means of proving an injury caused by false advertising.

Because the advertisements are
ongoing, there
was
also a
genuine dispute of fact as to the likelihood of future injury.

California law requires an “economic
injury”; there was also a material fact issue on that for the same reasons.

from Blogger http://tushnet.blogspot.com/2023/07/defendants-belief-its-ads-were.html

Posted in Uncategorized | Tagged , | Leave a comment

Former distributor’s continuing use of “authorized distributor” leads to TM and false advertising claims

Axon Enterprise, Inc. v. Luxury Home
Buyers, LLC, No. 2:20-cv-01344-JAD-VCF
,
|2023 WL
4636917
(
D. Nev. Jul. 19, 2023)

In what seems likely a missed
opportunity due to insufficient investment in the defense, the court grants
summary judgment against an argument that “Taser” is generic (quick quiz before
reading further: what is the generic name for a Taser device?) but also narrows
the issues somewhat; the larger infringement, cybersquatting, and false advertising
claims can’t be resolved on summary judgment.

Axon makes Taser “non-lethal
weapons” (but that can’t be the generic name—anything that encompasses a Taser
and a beanbag gun is clearly too broad). Defendant LHB is a former distributor
now selling
used Tasers that its owner
refurbishes in his home workshop. Axon
sued for infringement of the
Taser
word and design marks and for holding Taser-related
domain names for ransom.
Axon apparently characterizes its non-lethal
electric weapons as “conducted energy weapons.”

When it was an authorized Axon
distributor, LHB’s owner registered
various
domain names including taser.org and tasers.org to help it market Tasers
online. LHB currently owns 64 domain names containing references to Taser or
Axon Taser models.
And while
neither party knows exactly when their distributor relationship ended, they
agree that it ceased sometime around 2000.
” Does that sound like the
claims against the domain names might be lached?

On websites, emails, and mailers,
LHB uses
Axon’s Taser character, stylized
word, and design marks, often in proximity to its own marks. On several of its
websites, LHB also makes representations that it is an “Authorized TASER®
Distributor” and that “TASER® is a Trademark of the Mister Stungun.”

Its marketing also focuses on the
superiority of the Taser X26E CEW over other models
—that is of course
the refurbished model it sells, while Axon has moved on—
stating that the X26E “wield[s] the highest degree of
takedown power of total and absolutely unsurpassed effectiveness[;]” “offers
the highest degree of takedown power ever available with the same level of
safety[;]” “has the most powerful technology and stopping force[;] “lasts for
over 20 years—and works every time[;]” and has “twice the power” of the X26P
CEW.
LHB also advertises that its products
are “factory refurbished,” “professionally refurbished,” “thoroughly tested,”
“refurbished to the highest standard,” “completely refurbished” to “work like
new,” “even better than new,” and reprogrammed “with the latest software.”

Axon was entitled to summary
judgment on genericity. LHB offered only
two news
articles and a Ninth Circuit opinion that use the word “Taser” without the
trademark symbol
:

The mere fact
that two article authors and a Ninth Circuit panel utilized the mark without a
corresponding trademark symbol does not show as a matter of law that the
primary significance of “Taser” to consumers is as a type of good rather than a
source identifier. And the context of each reference was to refer to an Axon
product or to distinguish other products as alternatives to Axon’s weapons.

Even if they were generic uses, two
articles and one opinion weren’t sufficient to overcome the “strong presumption”
of validity of a registered mark.

Likely confusion: Obviously, this
is a nominative use. But is it a nominative fair use?
Toyota Motor Sales v. Tabari asks whether “(1) the product was ‘readily identifiable’
without use of the mark; (2) defendant used more of the mark than necessary; or
(3) defendant falsely suggested [it] was sponsored or endorsed by the trademark
holder.”

The court rejected Axon’s argument
that LHB could have identified its products by calling them CEWs; they were
Taser brand products. However, it used more of the marks than reasonably
necessary, favoring Axon (the court seems to be treating this as a balancing
test, to be finalized in the third factor). The court applies the non-empirical
but fairness-based line of 9th Circuit cases stating that using logos and not
just names risks confusion. (When I see these claims I think about all the
businesses using Facebook, Twitter, LinkedIn etc. logos on their materials to
identify their social media accounts. Does anyone think that increases the
likelihood of confusion over affiliation? Just as with first sale, there is an
unambiguous truth—I have a legit product to sell, I have an account on this
site—coupled with a less-significant possibility of confusion about whether
there’s a greater relationship than that. I don’t think using the logo
guarantees confusion, but the context of social media may be much more
clarifying than the context of resales.)

Most importantly, there were
genuine issues of fact about whether LHB suggested
Axon’s sponsorship or endorsement. LHB argued that
it
avoided consumer confusion by fully disclosing that
its products are refurbished and by maintaining the basic nature of the Taser
through the refurbishment process.
“A
xon responds
that the first-sale doctrine isn’t dispositive of this prong because
affiliation confusion can still exist for disclosed refurbished products.

 

As the Ninth Circuit held in Sebastian International v. Longs Drug Stores,
first sale
doctrine “is not rendered
inapplicable merely because consumers erroneously believe the reseller is affiliated
with or authorized by the producer.” The Sebastian court thus held that,
“[w]hen a purchaser resells a trademarked article under the producer’s
trademark, and nothing more, there is no actionable misrepresentation.”

Still, that’s limited to using the
trademark on a resold article and its immediate packaging, but not using stylized
marks
and logos on advertising materials. Axon didn’t seek to
enjoin the sales of refurbished Tasers.

Axon’s evidence of actual confusion was three emails from various police officers and personnel
inquiring about any affiliation between Axon and LHB, as well as declarations
from
two officers
that they
were confused about an affiliation between the parties.
LHB pointed out
that it
markets to thousands of police
departments,
and one
declaration
only states that he was under the belief that LHB “could be affiliated with
Axon
.” Still, that was enough to create a genuine issue of fact. [Note
that the cases are just divided on this—inquiries and uncertainty often indicate
that the inquirers correctly understood that they needed to know more before
concluding that there was an affiliation. Compare this to the treatment of ambiguity
in advertising law—outside of trademark, courts make consumers work much
harder.]

The context of the use also
mattered. Axon pointed to
LHB’s
phrases such as “100% certified to work like new,” false description of itself
as “an [a]uthorized TASER® distributor”
(this was, LHB argued, an
oversight on some of its websites left over from when that was true),
use of Axon’s
stylized mark in the top left corner of every single page on
accreditedsecurity.com, and incorporation of Axon’s globe/bolt logo into that
same page.
It argued
that LHB’s
disclaimers
were
ineffective at curing confusion
because of their placement alone—they appear in small font at the bottom of
LHB’s website and are thus “buried and easy to miss.”
However, the
disclaimers were not ineffective as a matter of law. Whether LHB suggested
affiliation was an issue of fact.

False advertising: As noted above,
LHB made superiority claims for the model it sold; claims that its products
were
“factory refurbished,” “professionally refurbished,”
“thoroughly tested,” “refurbished to the highest standard,” “completely
refurbished,” “work like new,” and reprogrammed “with the latest software”
;
and
affiliation statements that it is an “[a]uthorized
TASER® [d]istributor” and “TASER® is a [t]rademark of the Mister Stungun.”

The product superiority claims
failed. Although these statements weren’t puffery, but specific and measurable,
they weren’t shown to be false either. Although LHB admitted it never tested
that model against others, it relied on “
two media
articles, his personal opinions, stories from his customers, and unspecified
google searches.

But this wasn’t a “tests prove”
case. [Did the statements inherently suggest the existence of scientific
research backing them up? I might’ve gone the other way on this.] Thus, showing
that reliable studies didn’t support the claims didn’t suffice to falsify them.
Axon didn’t submit any evidence of falsity. The closest it got was an expert
report
stating that “Axon has established a
5-year useful life for its CEW products and strongly discourages … use of
CEWs beyond their 5-year useful life.”
But a
manufacturer’s strong recommendation of a product’s useful lifespan does not
show that the device cannot last for more than 20 years.

Refurbishment quality: Axon argued that LHB’s
Tasers cannot be “factory refurbished” because the process takes place only in
its
principal’s
home or in the homes of his
independent contractors; nor “professionally refurbished” because
he
has no degree or expertise in mechanical engineering; nor
“thoroughly tested” because LHB does not run independent testing other than
superficial inspection; nor “refurbished to the highest standard” because LHB
identified no standards it was using; nor “completely refurbished” to “work
like new” because Tasers are sonically welded together such that their internal
components cannot be examined or replaced. And finally, while Axon agrees that
LHB’s Tasers might be reprogrammed “with the latest software,” it argues that
such a claim is misleading because the last X26E firmware update was in 2014
and
LHB
does not have access to the most
recent updates for two of the other Taser models he sells
.

LHB responded that each Taser “undergoes several aesthetic and functionality
inspections” in which he “installs new batteries, new firmware, cleans any
internal carbon build-up in the front cartridge, clears any error codes, and
ensures each element of the [display] functions properly.”
Its principal
maintains a “designated space [that] LHB references
as a ‘factory’ area to perform the refurbishment process.”

The court found that reasonable jurors
could disagree about the “subjective” meanings of the claim. [Doesn’t that mean
that evidence of consumer deception is required, in the absence of literal
falsity?]

Affiliation statements: Everybody
agrees that neither
“[a]uthorized TASER® [d]istributor”
nor
“TASER® is a [t]rademark of the Mister Stungun”
is true. But Axon still needs to show deception and materiality. Literal
falsity leads to a presumption of materiality and deception, and “[n]
othing in the record suggests that those presumptions
should not apply here.
” [This might be a good case for why there shouldn’t
always be such a presumption, although I think it should still exist in many
cases; neither “always” nor “never,” the more recent judicial trend, is ideal.]

But Axon wasn’t just seeking a
permanent injunction; it sought compensatory damages, but pointed to no evidence
of actual injury or damages from the false affiliation statements. It lost
summary judgment on damages but won summary judgment as to injunctive relief.

Trial only on
LHB’s refurbishing-quality statements.

Nevada deceptive trade practices:
Similar results, but somewhat different remedies for the affiliation statements.
LHB knew it was aware the distributor relationship was over well before Axon
filed suit.
Nevada’s law allows a court to require a liable party “to pay to the aggrieved party
damages on all profits derived from the knowing and willful engagement in a
deceptive trade practice and treble damages on all damages suffered by reason
of” that practice.
And its

consumer-fraud statute requires a court to award a deceptive-trade-practices
claimant “any damages that the claimant has sustained; any equitable relief
that the court deems appropriate; and the claimant’s costs in the action and
reasonable attorney’s fees.”
Thus, Axon could recover damages and
attorney’s fees but would have to prove the amount.

Then, surprisingly reversing the result
on the product superiority statements in the Lanham Act context, the court says
that although there’s no evidence of falsity, “
Nevada law
imposes liability for disparaging claims based on true-but-misleading
statements
,” so that would have to go to trial. But the Lanham Act also
imposes liability for true-but-misleading statements; it just requires evidence
that consumers were misled to do so—here, about the nature and quality of LHB’s
supporting evidence. Having a different result on the state law claim is
conceptually weird but does highlight that traditional common-law claims are
more likely to be decided on vibes, whereas Lanham Act false advertising has adopted
a technocratic, probabilistic structure that often demands survey or other
empirical evidence.

The court also denied summary
judgment on the ACPA claim, even though one of
LHB’s
websites
listed
its various Taser-related domains
with a headline banner labeled “Domain Names for Sale.”
The court agreed
that bad faith could arise after registration of a domain name. Still, there
were genuine disputes over bad faith because the prior distributorship, and
current sales of refurbished Tasers, weighed against things like LHB’s offer to
sell the domain names to Axon. Even redirecting four of the contested domains
to porn sites didn’t sufficiently show intent to tarnish the Taser mark for
summary judgment purposes.

Laches (I wondered!): Although Axon had knowledge of some of the contested domains since
at least 1999,
LHB didn’t fully analyze the laches standard or
offer evidence that it suffered prejudice from delay. Summary
judgment for LHB on laches denied.

from Blogger http://tushnet.blogspot.com/2023/07/former-distributors-continuing-use-of.html

Posted in Uncategorized | Tagged , | Leave a comment

over aggressive partial dissent, 11th Cir. allows some class claims against Ford “track ready” claims to proceed

Tershakovec v. Ford Motor Company, Inc., — F.4th —-,
2023 WL 4377585, No. 22-10575 (11th Cir. Jul. 7, 2023)

Discussion
of district court opinion
. Ford advertised its Shelby GT350 Mustang as
“track ready.” “But some Shelby models weren’t equipped for long track runs,
and when the cars overheated, they would rapidly decelerate. A group of Shelby
owners sued Ford on various state-law fraud theories and sought class
certification, which the district court granted in substantial part.” Ford appealed
and the court of appeals tinkered with the certification, over a dissent that
thought that enforcing consumer protection laws in this case would violate the Constitution
in multiple ways (edging close to the claim that the class action mechanism
violates Article III).

The key question was predominance, which depended on whether
the specific state laws at issue required proof of reliance, whether reliance
could be presumed, and if so under what circumstances.

As for the facts:

The Shelby is an upgrade of the
standard Mustang and, importantly here, was advertised as “an all-day track car
that’s also street legal.” Track-capability refers to the vehicle’s capacity to
perform at higher-than-normal speeds in a controlled environment—like, say, on
a racetrack. Track-readiness was a central theme in Ford’s Shelby advertising.

Yet, of the five Shelby trims, the Base and Technology trims
lacked “transmission and differential coolers,” a feature—originally included
as standard on all Shelbys—that is designed to prevent engine overheating.
Without them, the Shelbys compensate at high RPMs by reverting to “limp mode,” which
reduces the vehicle’s power, speed, and performance to avoid engine damage—and
is inconsistent with track-capability.

“On appeal, twelve separate claims remain, arising under the
laws of seven states: California, Florida, Missouri, New York, Tennessee,
Texas, and Washington.”

The parties focused on reliance, so the majority did as
well, dismissing the dissent’s claim that reliance and causation are inherently
intertwined as inconsistent with governing state law. See, e.g., Carriuolo v.
Gen. Motors Co., 823 F.3d 977, 983, 986 (11th Cir. 2016) (Florida) (holding
that plaintiffs “need not show actual reliance on the representation or
omission at issue,” even when causation is an element). Thus the majority also
declined to address the manifold constitutional claims made by the dissent.

The majority did, however, find that the district court
erred by overgeneralizing the set of cases in which reliance can be presumed to
those cases where a defendant’s representations to the entire class were
uniform. But this can only be done if the underlying state law allows for it. “Affirmatively
proving reliance is a very individualized inquiry, the kind that would
predominate over other common questions in a class action. By contrast, where
the presumption of reliance applies, it does so generally and can therefore be
resolved on a class-wide basis.”

And then the majority does something very weird, albeit (it
says) prompted by the parties’ concessions. It says that presuming reliance
from materiality often is only appropriate where the cause of action is
omission-based, relying on cases decided under the federal securities laws. I
have no idea why those are relevant (and indeed the majority seems to
understand that California, at least, does not take that position, agreeing
with the district court that a uniform material misrepresentation can lead to a
presumption of reliance).

From that, the court then rejected plaintiffs’ argument that
this was an omissions case; at its core, this case was about
misrepresentations, not omissions. And it rejected plaintiffs’ invocation of Klay
v. Humana, 382 F.3d 1241 (11th Cir. 2004), abrogated in part on other grounds
by Bridge v. Phoenix Bond & Indem. Co., 553 U.S. 639 (2008), for the
proposition that common evidence about misrepresentations can be used to prove
reliance on a class-wide basis, because there the misrepresentation that a HMO
would pay for procedures was the central factor driving the transaction. “While
one who provides services in exchange for a payment relies only on the payment
guarantee, a purchaser of a car may choose to rely on any of a number of
marketing and branding representations.” (I mean, so might the provider of
medical procedures, especially in a world where they can sue the patient for
any underpayment; this bright line does not seem consistent with many state law
decisions I’ve seen and seems to underweight the idea of material
misrepresentation in particular.)

With that out of the way, claims based on state laws that
didn’t require reliance could proceed on a classwide basis, and claims based on
state laws that didn’t presume reliance couldn’t. For claims based on state
laws that sometimes presume reliance, the majority examined whether reliance
could be presumed.

No reliance required: Florida Deceptive and Unfair Trade Practices
Act; N.Y. Gen. Bus. Law § 349(a); Washington’s consumer-fraud statute; and the Missouri
Merchandising Practices Act.

No presumption of reliance, therefore no certification: Texas
Deceptive Trade Practices-Consumer Protect Act and common-law fraud claims
under Washington, New York, and

Tennessee law.

Causes of action that require proof of reliance but allow it
to be presumed in certain circumstances: The usual
California claims
, both statutory and common-law, fell in this category. On
remand, the district court should consider whether “the defendant so
pervasively disseminated material misrepresentations that all plaintiffs must
have been exposed to them.” If so, certification would be appropriate.

But California and Texas classes for breach of implied
warranty and violations of the federal Magnuson-Moss Warranty Act required
further analysis. The district court first needed to decide “whether California
and Texas law require pre-suit notice, an opportunity to cure, and
manifestation of the defect.”

Superiority: “Ford fears that jurors will have to remember
testimony from multiple witnesses, all while keeping track of the class
members’ states, the applicable common-law rules and statutes, and burdens of
proof.” The district court thought that “appropriate jury instructions” and
“multiple verdict forms that tick through the [varying] elements of [the]
certified state class[es]’ statutory and common law fraud claims” would
suffice, but the majority was more worried. Given that some of the claims had
been kicked out, on remand the court “should consider the manageability
challenges anew on remand and should more clearly articulate a plan for
addressing them to ensure that the difficulties of managing the class action do
not impede the fair and efficient adjudication of the case.”

Senior Judge Tjoflat concurred as to the claims that were
tossed out and dissented as to the claims kept alive, engaging in a
wide-ranging rejection of state law precedents as unconstitutional or
inapposite or just wrong or all of the above. I didn’t know that federal courts
(other
than the Supreme Court
) were supposed to tell state courts they interpreted
state legislation wrong, and I suspect that’s one reason the majority doesn’t
engage with the dissent much. We’re obviously in a period of great
constitutional doctrinal change, and so disregarding positions as “off the wall”
is a risky game, but I will just sketch out what Judge Tjoflat says are the
constitutional problems rather than recount all the arguments state by state.  

The FTCA declares unlawful “[u]nfair methods of competition
in or affecting commerce, and unfair or deceptive acts or practices in or
affecting commerce.” That’s vague, but the FTC tells businesses they’re
violating the Act before punishment (I … didn’t think that was the standard for
avoiding unconstitutional vagueness). Importantly [for its constitutionality],
the FTCA doesn’t allow for damages or a private right of action. (!!!! Judge
Tjoflat mentions civil penalties, but doesn’t explain why in his view they are ok.)

Even when state laws explicitly refer to FTC standards,
then, they have different constitutional constraints because they authorize
private actions for backward-looking damages. But vagueness when barring
misrepresentation is less troubling than vagueness when barring unfairness,
including because misrepresentation comes with an inherent causal mechanism.
Plus, prior decisions under the statute can limit vagueness:  

First, we can look to prior
decisions under the statute. “Unfair business practice” might not in itself
tell a cruise ship company that it cannot charge customers an additional fee,
label it a “port charge,” then pocket some of that extra money as profit. But a
previous case decided by a court under the consumer protection statute dealing
with that situation would.

Or we can provide notice by using the common law definition
of fraudulent misrepresentation, where the common law provides the notice. (Treating
the common law as clear and natural and non-evolving is an important part of
the conservative judicial project, but it’s used so incoherently that I’ve
never been able to develop a full account.)

Either way, when there’s a misrepresentation, reliance is
required (I believe option 1 required reliance because the baseline was
requiring reliance so any previous case must have either imposed a reliance
requirement or announced a change.) Harm only occurs if there’s reliance (Judge
Tjoflat is no fan of price premium theories). Here, “[s]ome of the class
members (1) may not have seen the advertisements at issue, (2) may not have
wanted a track-ready car, or (3) wanted merely to collect the car without ever
driving it around the track.” They couldn’t have relied on the alleged
misrepresentation. [Especially for (3), that’s a bold factual claim.] No
reliance means no causation, and none of the statutes at issue here explicitly
disclaims reliance.

All those state court cases talking about contributing cause
versus but-for cause, or presuming reliance from materiality, don’t count,
because “by reading out a reliance element in all cases, a court usurps the
legislature’s power and attempts to bind future courts in a way inconsistent
with our conception of judicial power.” “Our” here is doing a lot of work, not
just in an ideological way but also in terms of putting Article III constraints
on state courts.

Certifying a class here therefore poses problems of free
speech, due process, separation of powers, and standing. [Oh look, the Article
III challenge to the class action mechanism I’ve been waiting for has arrived!]

Free speech: “While the First Amendment does not protect
untruthful commercial speech, the judicial elimination of a causation element
makes a speaker liable for speech with or without the speech actually harming
anyone. This chills protected speech.” It would be fine under the First
Amendment to enjoin deceptive commercial speakers or hold them liable for the
actual damage they cause, but not to assess damages even for consumers who
weren’t deceived. [And statutory damages? Punitives? Statutory penalties?] Even
though a consumer protection law only prohibits deceptive commercial speech, without
reliance, “any rational businessperson would stand so far away from the
ill-defined line between outlawed advertising and permissible advertising—thus
chilling protected speech—to avoid the potentially catastrophic consequences of
damages to all.” [No citation to cases about chilling commercial speech,
because the current doctrine is that commercial speech is hardy enough to
resist chill.] Prophylactically prohibiting “potentially misleading—and
therefore protected—speech” “goes well beyond that necessary to further a
state’s interest in protecting consumers from misrepresentation.” [That doesn’t
even follow! “Potentially misleading” is a new concept and not the same as “misleading”—or
at least it is currently.]

Due process: bound up with the above, but worse with a class
action. Where reliance ought to be an element of a claim, class actions violate
due process because unnamed plaintiffs might get relief without having a
meritorious individual claim. “Much as a court eliminating causation from the
traditional elements of negligence would deprive a defendant of property
without notice—thus denying the defendant due process—so would excusing the
reliance (and therefore causation) element in these state consumer protection
statutes.” It would be a judicial taking! [One thing that fascinates me is the
on/off characterization of causation, reliance, damages, etc. If one thinks
that presumptions and probabilities are appropriate subjects of legal rules,
this imagined field of infinite liability becomes much more bounded.]

Anyway, without reliance and thus causation, there’s also an
Article III standing problem. An objective test for a forward-looking injunction
is fine, but not for damages. “[E]ven though ‘Congress [or a state legislature]
may elevate harms that exist in the real world before [the legislature]
recognized them to actionable legal status, it may not simply enact an injury
into existence.’ ” TransUnion. Plus, the state shouldn’t be able to
delegate enforcement power into private hands because they aren’t
democratically accountable.

And finally, there’s a separation of powers problem because
any state court that announces that a state statute doesn’t require showing
reliance in a misrepresentation case has usurped the legislature’s power and
rewritten the statute. This makes the free speech problem worse because state
legislatures have the police power to protect citizens from injury, but courts
don’t.

And now we get to presumptions: a rebuttable presumption of
reliance can’t possibly apply to any of the claims in this case. Such
presumptions are only allowed when the party with the burden of rebuttal has
better access to the evidence, and consumers have better access than sellers to
evidence about what motivated them. [This is probably untrue as a matter of
consumer psychology and marketing knowledge, and it also doesn’t seem to me to
describe the full range of rebuttable presumptions that exist, either. Does the
TMA’s rebuttable presumption of irreparable harm to trademark owners put the
burden on the party who has most access to the evidence? This seems like “common
law as fixed, natural, and just as I think it should be” again.] Plus, allowing
Ford to rebut the presumption would make a class action unmanageable.

So it would have to be a conclusive presumption, which has all
the problems above: California courts shouldn’t have created it either for the
statutes or for the common law (even if it were correct about the statutory standard
“as a linguistic matter”). State courts holding otherwise aren’t entitled to
full faith and credit because they don’t “wrestle” with the constitutional
questions (and resolve them as Judge Tjoflat wants).

Likewise, though Florida’s FDUTPA explicitly requires courts
to interpret the statute by giving “ ‘due consideration and great weight’ to
Federal Trade Commission and federal court interpretations of section 5(a)(1)
of the Federal Trade Commission Act,” it makes “no sense” to say, as Florida
courts have, that because the FTC Act allows suits without proving reliance, so
should the FDUTPA. “How the FTC Act treats reliance has nothing to say about
the FDUTPA’s damages provision,” since the FTCA doesn’t allow private damages,
only prospective relief or “civil damages.” The court here should also ignore the
Michigan Supreme Court because it gave short shrift to due process concerns in
interpreting its own law.

Judge Tjoflat has been on the bench for decades, but I do
wonder whether he’d have written this opinion before a few years ago, given the
swing-for-the-fences approach many judges in his circuit are now willing to
take.

from Blogger http://tushnet.blogspot.com/2023/07/over-aggressive-partial-dissent-11th.html

Posted in Uncategorized | Tagged , , , , | Leave a comment

Covid-19 Act gives government more options in proceeding against supplement seller

U.S. v. Nepute, 2023 WL 4623089, No.
4:21-CV-437 RLW
(E.D. Mo. Jul. 19, 2023)

The US sued Nepute (a chiropractor)
and Quickwork (a company of which he is a member/co-manager). for deceptive
advertising of dietary supplements in violation of the FTCA and
the COVID-19 Consumer Protection Act. Here, the
court excluded/limited Nepute’s proposed experts, denied partial summary
judgment to Nepute, and granted partial summary judgment to the US on a few
issues, including whether the challenged materials were ads.

Since early
2020, Defendant Nepute and Quickwork have used several platforms, including
social media, emails, and radio, to tout the purported benefits of Vitamin D
and zinc and to promote Wellness Warrior supplements.
” The government
alleged that Nepute made false and misleading claims about the supplements,
including that
Wellness Warrior supplements
containing Vitamin D and/or zinc are effective for the treatment, cure,
prevention, or mitigation of coronavirus disease 2019 (“COVID-19”), and that
they provide equal or better protection against COVID-19 than available
vaccines.
Given its powers under the COVID-19 Act, the government sought
not just a permanent injunction, but damages, including recission/restitution/disgorgement,
as well as civil penalties.

The court excluded the testimony of
Dr. Parks, who had (as relevant)
a Ph.D. in
cellular and molecular biology in 1999
but hadn’t
conducted academic or peer-reviewed research since 2000;
none of this research related to zinc or any dietary supplement, or to covid.
 Since 2004,
she worked as
a high school teacher at a
homeschool co-op in Michigan.
Her education and research were
insufficient to qualify her t
o testify as
to the clinical benefits of zinc and the prevention and treatment of COVID-19
.

Defendant Nepute also couldn’t
testify as an expert (as opposed to as a fact witness). He has a 2007 Doctor of
Chiropractic degree and some post-doctorate training, including
certification as a Doctor of Natural Medicine and as a Certified Nutrition Specialist. He conducted no studies or research, led/participated
in no
clinical trials, and published no academic papers in any peer-reviewed journal. The primary focus of his practice is the treatment of neuromusculoskeletal
complaints and fatigue
; he
does not
treat disease in his chiropractic practice, and there
was no record of
any experience treating infectious diseases or
covid. He lacked
the education, training, and
experience to testify regarding the clinical benefits of Vitamin D and zinc to
prevent or treat COVID-19.

As a fact witness, the government
agreed that he could
supply what he claims is “the
scientific basis upon which he made the alleged misstatements”
for the
purpose of assessing whether he had sufficient substantiation for his claims.
 But he
couldn’t
testify as an expert on whether such
evidence
was
sufficient to satisfy the relevant
scientific community that Vitamin D and zinc can treat and/or prevent COVID-19.

Were the publications at issue ads?
In general, advertisements provide consumers with
information regarding products or services for sale in commerce.
Under Section 12 of the FTC Act, an “advertisement” is a
publication that has the “tendency or capability to induce the sale of [a]
product.” Publications “designed to convey the point that consumption of a
particular product [will convey a health benefit] are clearly likely to induce
the purchase of that product.” It
was
undisputed
that Nepute used several platforms to share the purported benefits of Vitamin D
and zinc and his Wellness Warrior supplements
, including
Facebook videos, emails, and FM radio shows. Along
with the claims, consumers were directed to websites where they could get a “free”
bottle and buy additional bottles.

Nepute argued that these were just
educational materials and argued that,
“in many
cases, listeners were directed to the Quickwork website[s] for the express
purpose of providing further health information.”
Because the websites
do more than simply sell vitamins and supplements – they
are “interconnected with the exposition of ideas about how to live a healthy
life” –
he argued that references to the
websites in the publications didn’t make them ads, and
that his content was “infused with political speech
.” First, Nepute didn’t offer a First Amendment
defense in the answer and couldn’t do so now. But even if he had, his speech
was not entitled to First Amendment protection: The publications were
commercial speech, and there were fact issues on falsity/misleadingness, for
which he could be held liable.

The evidence didn’t support the
claim that the websites were used as educational references. E.g.:

So here’s
what I want you to do. Go to freevitamindeals.com – that’s freevitamindeals.com
so that you can get the products that you need. I’m giving you a bottle of zinc
for free, a bottle of D3 for free. I need you to buy that immune pack. You’d be
silly not to get it. If you don’t want to, that’s fine. But I’m just telling
you what you need to do. According to the research, it’s what you should be
doing.

By the delivering the message about
the benefits of Vitamin D and zinc
in
conjunction with providing the websites where viewers and readers could
purchase Vitamin D and zinc, the videos and emails were clearly likely to
induce the purchase of these products.

The radio shows were a closer call;
they were two hours long and weren’t limited to
Vitamin D and zinc, or even COVID-19, vaccines, or other
available treatments.
But the parts that the government was challenging
were ads: “
During the radio programs themselves
– outside the scheduled commercial breaks – Defendant Nepute made statements
that the consumption of Vitamin D and/or zinc will provide certain health
benefits; he delivered his message in conjunction with providing websites where
listeners could purchase Wellness Warrior Vitamin D and zinc supplements; and
he instructed, either explicitly or by clear implication, that listeners should
purchase vitamins and/or supplements.

The government can show either
falsity/misleadingness or lack of substantiation to prevail. The government was
entitled to summary judgment on the issue that there is
no substantiation for representing that Vitamin D and/or zinc provide equal or
better protection against COVID-19 than the vaccines, to the extent Nepute made
such a claim in his advertisements
. (He argued that he didn’t, and that
he was just attacking the efficacy of the vaccines without making comparisons.
Sure.) It also received summary judgment that there was no substantiation for a
claim
that zinc is effective for preventing and treating
COVID-19
.

Materiality: there was no dispute
that the challenged claims were material. “
This would be
especially true during the COVID-19 pandemic.
” Also summary judgment for
the government.

However, there was a fact issue of
whether all the ads at issue made those claims.  

The videos
and radio shows appear to have been unscripted, impromptu performances, which
at times were rambling and disorganized. Certainly, Defendant Nepute made
assertions about Vitamin D, zinc, COVID-19, and the vaccines, among other
things, in his advertisements, but he often jumped from topic to topic and did
not make connections between his statements. Furthermore, some of the
representations he made about Vitamin D and zinc were vague or ambiguous.
Drawing inferences most favorable to Defendant Nepute, the Court finds the
issue of whether representations made in each of the 64 advertisements created
the net impression that either (1) Vitamin D and/or zinc provide equal or
better protection against COVID-19, or (2) that zinc is effective for preventing
and/or treating COVID-19, is a matter for the Government’s presentation of
evidence at trial and determination by the jury.

Nepute’s individual liability: An individual is liable for a company’s violations of the
FTC Act if he (1) “either participated directly in the deceptive acts or
practices or had the authority to control them”; and (2) “either knew or should
have known about the deceptive practices.”
It was undisputed that he both
controlled and participated in the practices and knew about the contents, so
the government also got summary judgment here.  

Number of violations: The government
calculate
d
that the 16 Facebook videos, 33
emails, and 15 radio shows have been disseminated 10,175,234 times for purposes
of the COVID-19 Act,
apparently by adding
the number of “views” for the videos on Facebook, the
number of email addresses to which the email advertisements were sent, and the
number of “views” the radio shows had after they were posted on Facebook and
CloutHub.
But there were factual disputes about how “views” are counted
on Facebook, and the court signaled its discomfort with that kind of raw
counting. Even if each unlawful letter in a mass mailing is a separate
violation, “[p]
osting videos and radio shows on
social media is entirely different than calling consumers or sending letters,
as the latter are targeted forms of communication where
the number of intended recipients is readily calculable.
” [That would
seem to give a premium to using mass/social media to disseminate false ads,
which seems like the opposite of the right incentive.] The court wanted more
from the government when it asked the jury to find liability for a number of
violations.

Nepute argued that the government
wasn’t entitled to civil penalties
under the
COVID-19 Act, because the evidence
didn’t
support a finding that he knowingly violated the Act.
The relevant standard required a showing that
Nepute acted
“with actual knowledge or knowledge fairly implied on the basis of objective
circumstances that such act is unfair or deceptive and is prohibited” by the
COVID-19 Act. Knowledge can be “fairly implied” where “a reasonable and prudent
man under the circumstances would have known of the existence” of a statute or
regulation, and “that the action charged violated that provision.”

The COVID-19 Act was enacted on December 27, 2020. On March
30, 2021, the FTC sent a letter enclosing a copy of the COVID-19 Act to Nepute’s
attorney, informing Nepute that the Act “provides that marketers who make
deceptive claims about the treatment, cure, prevention, or mitigation of
COVID-19 are subject to a civil penalty[.]”
It
filed suit on April 15, 2021. Nepute argued that he
didn’t know about the
COVID-19 Act before March 30, 2021, and he had no knowledge that he might be
in violation of it prior to the filing of this lawsuit.
But, in May
2020,
the FTC sent a letter to him stating he was unlawfully advertising that supplements
Vitamin C and D can treat or prevent COVID-19. It is undisputed that
he
was advised in this letter to review “all other claims
for your products and services and immediately cease making claims that are not
supported by competent and reliable scientific evidence.”
Also there was
evidence that
Nepute had marketed vitamins and
supplements for at least a decade, and that he kept abreast of the news and
participated in legislative decision-making related to Vitamin D, zinc, and
COVID-19.
A jury could accept that “
a reasonably
prudent person, with over a decade of experience in vitamin and supplement
marketing, and who advertises on behalf of a multimillion-dollar supplement
enterprise, would have been aware of a major federal consumer protection
statute implicating his business and marketing.

 

from Blogger http://tushnet.blogspot.com/2023/07/covid-19-act-gives-government-more.html

Posted in Uncategorized | Tagged , , | Leave a comment

“24 Hour” cosmetics could be misleading as to sunscreen effect

Zimmerman v. L’Oréal USA, Inc., 2023
WL 4564552, No. 22-cv-07609-HSG (N.D. Cal. Jul. 17, 2023)

This is another lawsuit
over “24 Hour” cosmetics
, this time focusing on the fact that the
sunscreen in the products needs to be reapplied every 2 hours, making it more a
2-hour beauty line. The foundation’s front label statements claim it provides
“Up to 24HR Breathable Texture,” “Up to 24H Fresh Wear,” and “Sunscreen Broad
Spectrum SPF 25,” but the drug facts panel, located underneath a peel-back
sticker on the back label, directs users to “reapply at least every 2 hours”
for sunscreen use.

Zimmerman didn’t
have standing for two identified, unpurchased products—L’Oréal Pro-Glow
Foundation and Lancôme Foundation—where the alleged misrepresentations were not
substantially similar to L’Oréal Infallible Foundation, the product Zimmerman
purchased. L’Oréal Pro-Glow Foundation advertises “Up to 24HR Foundation,” and
Lancôme Foundation advertises “Up to 24H Color Wear & Comfort.” As for
other products, the court couldn’t assess substantial similarity without images
or detailed descriptions of the labels.

Zimmerman had standing
to seek injunctive relief, because she might not be able to tell if the labels
are accurate if L’Oréal changes the SPF protection duration; or, if L’Oréal alters
the front label to state that the SPF only lasts two hours and lowers the
price, she might be willing to pay. (I’m not sure the first is technically
possible, but I also don’t think it’s unreasonable for consumers not to know
that.)

There was no FDCA
preemption.  

And it was
plausible that a reasonable consumer could be deceived. L’Oréal argued that the
24-hour statements clearly referred only to cosmetic benefits, but the court
disagreed; “a reasonable consumer could believe the statements also include SPF
protection and would not see the reapplication instructions at the time of
purchase because they are buried underneath a sticker.” Where “a front label is
ambiguous, the ambiguity can be resolved by reference to the back label.” The
front label statements were ambiguous; “24H Fresh Wear” and “24HR Breathable
Texture” could be interpreted to include sunscreen protection. But it wasn’t
clear that the ambiguity could be resolved by reading the back. “The Court
cannot conclude as a matter of law that a reasonable consumer would peel back
the label in the store, before purchasing the product, to find and read these
instructions.”

from Blogger http://tushnet.blogspot.com/2023/07/24-hour-cosmetics-could-be-misleading.html

Posted in Uncategorized | Tagged , | Leave a comment

False advertising and TM infringement receive very different damages treatment: case in point

CareDx, Inc. v. Natera, Inc., No. 19-662-CFC, 2023 WL
4561059 (D. Del. Jul. 17, 2023)

Another entry in the “courts treat Lanham Act false
advertising very differently than Lanham Act trademark infringement, despite
identical damages provisions” line. Natera made superiority claims for its
Prospera. CareDx
sued Natera for false advertising
. In a trial held last year, the jury
found that CareDx proved by a preponderance of the evidence at trial that: (a)
nine of the ten alleged false advertisements were false; (b) Natera
intentionally and willfully engaged in false advertising; (c) Natera was liable
for false advertising under the Delaware Deceptive Trade Practices Act; (d)
Natera was liable for unfair competition; and (e) Natera intentionally or
recklessly engaged in unfair competition. It also found that CareDx was
entitled to $21.2 million in actual damages “attributable to Natera’s false
advertising and/or unfair competition,” and that CareDx was entitled to $23.7
million in punitive damages “for Natera’s unfair competition.” The court
rejected the damages award.

Actual deception—reliance on the falsity—must be proven to
establish damages for a Lanham Act violation, even if based on an unambiguous
and literally false advertisement. (The missing step is treating state and
federal claims the same here, which presumably everyone already agreed to.)

The jury was instructed that:

to recover damages under the Lanham
Act, the plaintiff must prove by a preponderance of the evidence that, one, the
defendant’s false advertising actually deceived a portion of the purchasing
public in that customers relied on the false advertising in making a purchasing
decision. There’s no presumption here for the damages question. The burden
rests on the plaintiff to prove that by a preponderance of the evidence.

All right. And then the second
thing that the plaintiff must prove by a preponderance of the evidence is that,
as a result of the false advertising, the plaintiff sustained injury. If you
find that CareDx proved these things, then you consider what amount of money to
award to CareDx as damages.

But, the court concluded, there was no evidence at trial that
any person was deceived by or relied on any of the nine advertisements found by
the jury to be false. CareDx’s evidence “does not establish directly or even
circumstantially that a person was in fact deceived by or relied on Natera’s
advertisements.” Specifically, Natera internally characterized a PowerPoint
slide that contained at least one of the false advertisements as “the money
slide.” “But that testimony is not probative of actual customer behavior.”

Nor did significant sales growth linked to the marketing
campaign at issue.  

Natera’s marketing plans and its training of marketing
personnel were also insufficient. “Proof of what Natera intended to accomplish
or thought it could achieve with its marketing plans and training efforts in no
way establishes that those plans and efforts succeeded.”

Compare the treatment of intent/expectation on the trademark
side: It is basically inconceivable that a court would reason this way in a
trademark damages case, despite the same statutory language for both.

The court also found that the following testimony didn’t
show reliance:

Counsel: And did this concern you,
that they were marketing that their specificity was better in the Sigdel study
than in the Bloom study?

Witness: You [counsel] kind of
mentioned how many phone calls I got from the University of Pennsylvania, from
Cleveland Clinic, from all around the country about their claiming superiority
based on what, they have a better assay. So this caused a lot of confusion
internally and externally with our customers.

Another witness:

Counsel: So does it matter whether
the other party is claiming superiority or not?

A. Absolutely.

… You know, these two publications
are ones that are not apples to apples, and they’re going around as if they are
and confusing clinicians, confusing patients.

“No rational juror could conclude from this vague,
conclusory, and hearsay-riddled testimony that customers were deceived by or
relied on false advertisements published by Natera.” In a trademark case, it’s
much less likely that this would be considered hearsay, but instead reporting mental
state.

Still, “in the Third Circuit, evidence of an intent to
mislead does not warrant a presumption of actual deception.” Judgment as a
matter of law on Lanham Act damages for Natera. Thus, CareDx also failed to
establish the causation and injury required to sustain a damages award arising
from its state law claims (and this also doomed the entire state unfair competition
claim).

However, there was sufficient evidence of literal falsity. For
example, the jury found literally false Natera’s claim that Prospera is “[m]ore
sensitive and specific than current assessment tools across all types of
rejection.” But Natera’s designated corporate representative admitted at trial
that two studies showed that Prospera’s specificity was lower than AlloSure’s
specificity and that AlloSure was a “current assessment tool[,]” as that phrase
is used in the advertisement. Natera argued that the claim was ambiguous and
thus not literally false because the phrase “sensitive and specific”
“reasonably refers to ‘AUC’—a measure familiar to physicians that combines both
sensitivity and specificity.” But ambiguity is a fact question for the jury.

The DTPA doesn’t require actual confusion, so there was
still liability.

If the judgment was later vacated or reversed, a new trial
would be required.

from Blogger http://tushnet.blogspot.com/2023/07/false-advertising-and-tm-infringement.html

Posted in Uncategorized | Tagged , | Leave a comment

no duty to defend despite allegations of label copying; but insurers can’t recoup defense costs already spent

Continental Casualty Company v. Winder Laboratories, LLC,
— F.4th —-, 2023 WL 4504183, No. 21-11758 (11th Cir. Jul. 13, 2023)

Winder, a generic pharma manufacturer, sought insurance
coverage for a false advertising lawsuit. The court of appeals affirmed the
finding that there was no coverage, but also that Winder didn’t have to pay the
insurers back for the representation they offered during the coverage dispute.

As relevant “personal and advertising injury” was defined to
include an injury “arising out of” either “[o]ral or written publication, in
any manner, of material that slanders or libels a person or organization or
disparages a person’s or organization’s goods, products or services” or “[t]he
use of another’s advertising idea in [the insureds’] ‘advertisement.’ ”1 The
policies also had a “failure to conform” provision that excluded coverage for
injuries “[a]rising out of the failure of goods, products or services to
conform with any statement of quality or performance made in [the insureds’]
‘advertisement.’ ” Neither policy at issue included a reimbursement provision
allowing the insurers to recoup defense costs.

The underlying lawsuit by Concordia asserted various claims
under the Lanham Act and Georgia law, focusing on the allegation that Winder
“falsely or misleadingly advertised their B-Donna product, and subsequently
their Phenohytro product, as generic [equivalents] to [Concordia’s product]
DONNATAL directly to the pharmaceutical industry, including to potential
purchasers.”

The insurers agreed to defend, subject to a reservation of
rights to disclaim coverage, but also included a “not-so-standard reimbursement
provision”: “VFI specifically reserves its right to seek reimbursement of
defense costs incurred on [the insureds’] behalf for all claims which are not
potentially covered by the VFI Policy.” The insurers also sued for a
declaratory judgment that they had no duty to defend or indemnify.  The district court held that Concordia’s
allegations were “squarely” excluded by the “failure to conform” provision
because the “operative complaint [was] based entirely upon allegations that
[Winder] misrepresented the quality” of Winder’s products.

Winder argued that Concordia’s complaint alleged a “personal
and advertising injury” because it included allegations that Winder copied
Concordia’s DONNATAL label inserts. But did the false advertising claim hinge
on the alleged label copying? If so, there would be coverage; if not, and the claim
rested on allegations that Winder actively misrepresented its drugs, then the
alleged injury arose from the “failure of goods … to conform with any
statement of quality or performance made in [the insureds’] ‘advertisement,’ ”
and the insurers were protected by the “failure to conform” exclusion.

The court of appeals agreed with the latter approach. The
copying allegations were clearly in service of the misrepresentation of
equivalence claim—copying was merely one of the means by which the misrepresentation
was allegedly carried out. This was not a “personal and advertising injury”
stemming from “[t]he use of another’s advertising idea”—i.e., Concordia’s
labels. The specific allegation that Winder made “false or misleading”
representations and statements about its products by “marketing the products as
‘generics’ that are comparable to and/or substitutable for [Concordia’s]
DONNATAL,” was a “textbook” of failure-to-conform.

Also, Winder argued that Concordia’s false advertising claim
relied on statements made by non-party drug databases for which Winder wasn’t
responsible; but Concordia clearly alleged that Winder’s initial alleged misrepresentations
were the but for cause of its injuries. Winder further alleged that it only
made true statements which couldn’t “fail … to conform with any statement of
quality or performance ….” However, the underlying complaint, which
determined coverage, alleged misrepresentations.

At least Winder wasn’t required to reimburse the insurers. “[B]ecause
insurers under Georgia law have a broad duty to defend when there is ‘even
arguably’ a covered claim, the insurers had an active duty to defend up until
the point when the district court ruled otherwise. Simply put, under the facts
of this case, the insurers were under a duty to defend until the district court
ruled that they were not.” No new contract was created by the insurers’
reservation of rights letter, and just asserting a right to reimbursement in a
reservation of rights letter isn’t enough if the insurance contract did not
contemplate a right to recoupment.

There was no consideration for the reimbursement provision. Importantly,
“a promise to perform a preexisting contractual obligation does not constitute
consideration for a new agreement.” The parties’ contracts already required a
defense against certain third-party lawsuits, so the letters were no more than a
promise to perform an existing obligation. Further, the underlying contract
didn’t provide which party would select legal counsel, so offering Winder the option
to choose counsel didn’t give up anything on the insurers’ side.

Nor was Winder unjustly enriched by retaining “the benefit
of an expensive defense to which they knew they were not entitled.” Even
assuming this argument didn’t immediately fail due to the existence of a
written contract, there was nothing “unjust” about requiring the insurers to
fulfill their contractual obligations. “[W]e cannot say that an insured is
unjustly enriched when its insurer tenders a defense in order to protect its
own interests, even if it is later determined that the insurer did not owe a
defense.”

Georgia law wouldn’t require this, the court predicted. “The
duty to defend is extremely broad under Georgia law.” There was no majority
rule favoring recoupment nationwide; the current case law “appears to be
more-or-less in equipoise with the recent trend favoring the ‘no recoupment’
rule.” More importantly, in Georgia, the broad duty to defend is “foundational.”
But a rule allowing for broadscale reimbursement without any contractual
provision securing that right would collapse the duty to defend into the duty
to indemnify. “That is, if the duty to defend required insurers to mount a
defense but the defense was widely reimbursable upon a court’s determination
that no ongoing duty to defend exists, the duty to defend would simply become
the duty to indemnify.” [This seems technically untrue—you could have a rule
separating the duty to defend from the duty to indemnify as long as a court
agreed that the allegations of the complaint created the duty to defend but an ultimate
finding/narrowing of the case could avoid the duty to indemnify—but that kind
of distinction does at least push against the breadth of the duty to defend.]

from Blogger http://tushnet.blogspot.com/2023/07/no-duty-to-defend-despite-allegations.html

Posted in Uncategorized | Tagged , | Leave a comment

“stacked” car insurance is plausibly deceptive as useless for single vehicle

Peck v. Progressive Northern Ins.
Co., 2023 WL 2712390, — F.Supp.3d —-, No. 1:22-cv-00490-KWR-JFR (D.N.M.
Mar. 30, 2023)

Peck bought stacked
uninsured/underinsured motorist (“UM/UIM”) coverage on a single vehicle policy.
Stacked UM/UIM coverage permits an insured to aggregate the UM/UIM coverages on
all vehicles insured under a policy. But Peck alleged that stacked UM/UIM coverage
on a policy insurance for a single vehicle is illusory because the insured
receives no benefit for the additional premium.

The court thus declined to dismiss
Peck’s claim under New Mexico’s Unfair Insurance Practice Act (“No person shall
willfully collect any sum as premium or charge for insurance or other coverage,
which insurance or coverage is not then provided or in due course to be
provided (subject to acceptance of the risk by the insurer) by a policy issued
by an insurer as authorized by the Insurance Code.”). Insurance companies “have
a duty to disclose material facts about the policies they sell under the UIPA.”

Defendants argued that there was a
tangible benefit because the coverage available automatically increases if the
policyholder gets an additional vehicle, but there was an additional premium due
if that happened and the policyholder had the burden of notifying Progressive. And
insureds were entitled to stacking by default, unless there was a written
rejection. So it was unclear if there was any benefit to stacking a
single-vehicle policy. Plus, even if it wasn’t illusory, it could still be
deceptive for failing to disclose that there was no benefit to stacking a
single-vehicle policy.

There was no breach of contract
claim, but possibly breach of the implied covenant of good faith and fair
dealing claim, unjust enrichment, and a New Mexico Unfair Trade Practices Act claim
for the same reasons.

from Blogger http://tushnet.blogspot.com/2023/07/stacked-car-insurance-is-plausibly.html

Posted in Uncategorized | Tagged , , | Leave a comment

Seen in my travels

 Good cafe name:

Cafe sign reading "The Breakfast Club"

A handbag that probably requires some explanation to today’s students:

A handbag decorated with images of videotape cassettes bearing handwritten labels of well-known movies like Top Gun

from Blogger http://tushnet.blogspot.com/2023/07/seen-in-my-travels.html

Posted in Uncategorized | Tagged , | Leave a comment